Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Aug 9;24(11):1497–1501. doi: 10.1634/theoncologist.2019-0316

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2019 The Authors. The Oncologist published by Wiley Periodicals, Inc. on behalf of AlphaMed Press.

This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.

PMC Copyright notice

Forest plot of progression‐free survival by subgroups. All analyses are per independent radiology committee. Hazard ratios are unstratified with the exception of the analysis for all patients. Metastatic sites are per investigator.

*Eight patients in the cabozantinib group and 18 patients in the sunitinib group had unknown MET status.

†Ten patients in the cabozantinib group and 10 patients in the sunitinib group were Eastern Cooperative Oncology Group (ECOG) 2.

Abbreviations: CI, confidence interval; HR, hazard ratio; IMDC, International Metastatic Renal Cell Carcinoma Database Consortium; NE, not estimable; PFS, progression‐free survival; SoD, sum of diameters.